ANDA Submissions Continue Yo-Yo Pattern, Unlike Approvals
Executive Summary
After spike in March, generic drug application submissions drop 62% in April, while approval volume remains at monthly average.
You may also be interested in...
ANDA Approvals Break Record, May Set New Normal
FDA's June approval total is highest of GDUFA era, but does it signal a new elevated productivity level for the generics program?
ANDA Approvals Break Record, May Set New Normal
FDA's June approval total is highest of GDUFA era, but does it signal a new elevated productivity level for the generics program?
FDA Drug Pricing Policy Offers Short-Term PR Gain, More Long-Term Actual Benefit
Prioritizing ANDAs entering markets with fewer than three approved generics not expected to become a major advantage until first-cycle clearances increase.